ACXP
ACXP
NASDAQ · Biotechnology

Acurx Pharmaceuticals Inc

$3.52
+0.02 (+0.57%)
Financial Highlights (FY 2025)
Revenue
850.6K
Net Income
-189,460
Gross Margin
31.3%
Profit Margin
-22.3%
Rev Growth
+3.9%
D/E Ratio
0.68
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 31.3% 31.3% 31.3%
Operating Margin -27.8% -28.2% -27.6%
Profit Margin -22.3% -27.0% -24.6%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 850.6K 846.2K 822.4K
Gross Profit 266.6K 265.1K 257.7K
Operating Income -236,622 -238,253 -226,952
Net Income -189,460 -228,334 -201,883
Gross Margin 31.3% 31.3% 31.3%
Operating Margin -27.8% -28.2% -27.6%
Profit Margin -22.3% -27.0% -24.6%
Rev Growth +3.9% -4.1% +22.7%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 2.74M 2.37M 2.87M
Total Equity 4.04M 3.87M 3.90M
D/E Ratio 0.68 0.61 0.74
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -320,116 -324,230 -315,475
Free Cash Flow -189,627 -182,540 -129,892